Compare Meta Platforms Inc (META) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Meta Platforms Inc vs 10X Genomics Inc — how do they compare? Meta Platforms Inc trades at $648.47 (market cap $1.64T), while 10X Genomics Inc trades at $46.15 (market cap $5.48B). The key difference: Meta Platforms Inc is far larger — about 299.3× 10X Genomics Inc's market cap, and Meta Platforms Inc pays a 0.33% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| META | TXG | |
|---|---|---|
Market Cap | $1.64T | $5.48B |
Volume | 24,093,972 | — |
Sector | Media | Health |
52-Week High | $790.00 | $45.80 |
52-Week Low | $525.72 | $11.34 |
Enterprise Value | $1.65T | $5.02B |
Dividend Yield | 0.33% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
META trades at $647.42, up 0.22% today, with a bullish technical signal from moving averages and neutral oscillators. The stock shows strong fundamentals with a P/E of 23.49, net income margin of 32.84%, and consistent earnings beats. Recent news highlights the launch of its Muse Spark AI model and a $21 billion deal with CoreWeave, though it faces a youth addiction lawsuit in Massachusetts.
Outlook remains positive with analyst consensus at Buy (79.37%) and a $817.32 price target, supported by robust revenue growth and AI investments. Key risks include regulatory lawsuits and high capital expenditures. The stock presents a growth opportunity but requires monitoring of legal and competitive pressures.
TXG trades at $43.18, down 1.28% today, with a bullish technical signal and positive earnings momentum. The stock shows improving fundamentals with revenue growth to $642.82M in 2025 and narrowing losses, while maintaining a strong gross margin of 69.6%. Recent acquisitions and partnerships with Cleveland Clinic demonstrate strategic expansion in genomic diagnostics.
The outlook remains cautiously optimistic with analyst consensus at Buy (45%) and price target of $39.14. Key risks include continued negative profitability metrics and high valuation multiples, while catalysts include upcoming Q2 2026 earnings and platform adoption growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
